0001209191-19-011831.txt : 20190220
0001209191-19-011831.hdr.sgml : 20190220
20190220201233
ACCESSION NUMBER: 0001209191-19-011831
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190219
FILED AS OF DATE: 20190220
DATE AS OF CHANGE: 20190220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Myszkowski Kenneth Allen
CENTRAL INDEX KEY: 0001486672
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38042
FILM NUMBER: 19620259
MAIL ADDRESS:
STREET 1: ARROWHEAD RESEARCH CORPORATION
STREET 2: 201 SOUTH LAKE AVENUE, SUITE 703
CITY: PASADENA
STATE: CA
ZIP: 91101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARROWHEAD PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000879407
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 460408024
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 225 SOUTH LAKE AVENUE
STREET 2: SUITE 1050
CITY: PASADENA
STATE: CA
ZIP: 91101
BUSINESS PHONE: 626-304-3400
MAIL ADDRESS:
STREET 1: 225 SOUTH LAKE AVENUE
STREET 2: SUITE 1050
CITY: PASADENA
STATE: CA
ZIP: 91101
FORMER COMPANY:
FORMER CONFORMED NAME: ARROWHEAD RESEARCH CORP
DATE OF NAME CHANGE: 20040112
FORMER COMPANY:
FORMER CONFORMED NAME: INTERACTIVE GROUP INC
DATE OF NAME CHANGE: 20020509
FORMER COMPANY:
FORMER CONFORMED NAME: INTERACTIVE INC
DATE OF NAME CHANGE: 19940224
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-19
0
0000879407
ARROWHEAD PHARMACEUTICALS, INC.
ARWR
0001486672
Myszkowski Kenneth Allen
225 S. LAKE AVENUE
SUITE 1050
PASADENA
CA
91101
0
1
0
0
Chief Financial Officer
Common Stock
2019-02-19
4
M
0
8000
5.20
A
313607
D
Common Stock
2019-02-19
4
S
0
8000
18.00
D
305607
D
Stock Option (right to buy)
5.20
2019-02-19
4
M
0
8000
0.00
D
2010-04-04
2020-03-04
Common Stock
8000
235000
D
Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Represents first vesting date. Option vested over four years from date of grant.
/s/ Ken Myszkowski
2019-02-20